NA Proactive news snapshot: Fury Gold Mines, XPhyto Therapeutics, O3 Mining, Humanigen, Great Panther Mining...

Fury Gold Mines Limited (TSE:FURY) (NYSEAMERICAN:FURY) (FRA:AUN1) told investors it has identified two significant gold-in-till targets at the Éléonore South joint venture (ESJV), which it aims to advance towards drilling in the summer of next year. The ESJV in Quebec was formed in 2008 and Fury is the operator on behalf of its partners. It holds a 36.72% stake, while Azimut Exploration holds 26.57%. Les Mines Opinaca Ltée, which is a wholly-owned subsidiary of Newmont, holds 36.71% of the venture. XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF (FSE:4XT) and its exclusive German diagnostics development partner 3a-diagnostics GmbH announced the successful validation of their point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system.  In addition, XPhyto said European regulatory approval and commercial product launch in European markets are planned for the first quarter of 2021. The newly developed test system has demonstrated diagnostic level accuracy (sensitivity and specificity) in its ability to detect SARS-CoV-2 RNA within 25 minutes. Robustness, repeatability, and laboratory precision have also been confirmed. The test is designed to be conducted with only minimal laboratory processes and equipment. O3 Mining Inc (CVE:OIII) (OTCMKTS:OQMGF) reported Thursday a "spectacular" drill intercept from its Simkar zone within the Sector 3 of its Alpha property in Québec. The hole was sunk at the western extension of the Simkar zone and included an assay of 413 grams per ton (g/t) gold over 1.2 metres (m). Immediate follow-up drilling of this intercept is underway."This is a spectacular intercept and one which is associated with a well-developed structure and is flanked by two significant previous drill intercepts 200 metres away on each side," noted chief executive of O3 Jose Vizquerra. "With all of these holes about 600 metres from the historical mine, it strongly suggests the presence of an important ore shoot in the down-plunge extension of the Simkar. Our winter drilling program will continue targeting this area and so we look forward to receiving more results early in the new year." Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) has completed patient enrollment in its Phase 1 bioimaging study of ifabotuzumab to treat recurrent brain cancer -  glioblastoma multiforme (GBM). The primary goal of this Phase 1 trial is to evaluate the safety of ifabotuzumab and to recommend a dose for a potential Phase 2 study, either with ifabotuzumab or an antibody drug conjugate (ADC) based on ifabotuzumab. Humanigen's trial is located at the Olivia Newton-John Cancer Research Institute in Victoria, Australia and results are expected in the first half of 2021. Great Panther Mining Limited (TSE:GPR) (NYSEAMERICAN:GPL) (FRA:G3U) reported that it has re-started mining activities at its Topia silver and gold mine in Mexico following a voluntary suspension of operations last month due to COVID-19 health and safety concerns. The company noted that the suspension of operations lasted about 30 days and is not expected to impact its ability to achieve consolidated 2020 production guidance.  BevCanna Enterprises Inc (CSE:BEV) (QTCQB:BVNNF) (FRA:7BC) announced Thursday that its acquisition of Naturo Group Investments Inc will close on or before January 20, 2021. In a statement, BevCanna said the merger will create a comprehensive health and wellness beverage and natural products company, one that generates significant value for both organizations and brings together two exceptionally experienced and innovative leadership teams. Vancouver-based BevCanna said it will catapult the company into the unique position of becoming the only fully licensed, in-house, and white-label beverage manufacturing company that distributes both conventional and cannabis-based beverage and wellness products. The merger will provide it access to global, multi-channel distribution networks of traditional and cannabis sales channels. Falcon Gold Corp (CVE:FG) (OTCPINK:FGLDF) (FRA:3FA) said it had received conditional acceptance for its previously announced C$750,000 private placing from the TSX venture exchange to fund continued exploration on its existing properties, outstanding payables and general working capital. Units are priced at C$0.12 and comprise one Falcon share and one non-transferable warrant. Each warrant entitles the holder to buy a new share for C$0.20 for 36 months. Shares and warrants are subject to a four-month hold period. Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) revealed that its chief executive Christopher J. Moreau and chief science officer Dr Mark Williams, will be discussing interim data on the company's Phase 2b/3 clinical study of Ifenprodil for COVID-19 on an upcoming free BioPub webcast on December 17 that will be hosted by Dr. KSS at noon ET. The company invites interested shareholders, investors, members of the media and the public to listen. To join the webinar, please click HERE. https://us02web.zoom.us/j/83294585006